About Convergent Therapeutics
Convergent Therapeutics is a company based in United States founded in 2020 by Philip Kantoff.. Convergent Therapeutics has raised $130 million across 2 funding rounds from investors including Orbimed, RA Capital and Novo Holdings. The company has 4 employees as of December 31, 2022. Convergent Therapeutics offers products and services including CONV01-α and Radioantibodies. Convergent Therapeutics operates in a competitive market with competitors including Radionetics, Hinova Pharmaceuticals, Nymox Pharmaceutical, Madison Vaccines and Nuage Therapeutics, among others.
- Headquarter United States
- Employees 4 as on 31 Dec, 2022
- Founders Philip Kantoff
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Convergent Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$130 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series A
Jul 31, 2024
-
Investors
Orbimed
& 2 more
-
Employee Count
4
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Convergent Therapeutics
Convergent Therapeutics offers a comprehensive portfolio of products and services, including CONV01-α and Radioantibodies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targeted therapy using alpha radioantibodies for prostate cancer treatment.
Antibodies with alpha-emitting payloads for precise cancer cell targeting.
Unlock access to complete
Funding Insights of Convergent Therapeutics
Convergent Therapeutics has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $40.0M
-
First Round
First Round
(27 Apr 2023)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series A - Convergent Therapeutics | Valuation |
investors |
|
| Apr, 2023 | Amount | Series A - Convergent Therapeutics | Valuation | Orbimed , RA Capital Management |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Convergent Therapeutics
Convergent Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Novo Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Convergent Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Convergent Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Convergent Therapeutics Comparisons
Competitors of Convergent Therapeutics
Convergent Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Radionetics, Hinova Pharmaceuticals, Nymox Pharmaceutical, Madison Vaccines and Nuage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Develops small molecule based drug for multiple disease treatment
|
|
| domain | founded_year | HQ Location |
Provides research and development of novel drugs and diagnostic products for the aging population
|
|
| domain | founded_year | HQ Location |
Immunotherapies for prostate cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Drugs are developed for intrinsically disordered protein targets.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Convergent Therapeutics
Frequently Asked Questions about Convergent Therapeutics
When was Convergent Therapeutics founded?
Convergent Therapeutics was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Where is Convergent Therapeutics located?
Convergent Therapeutics is headquartered in United States.
Who is the current CEO of Convergent Therapeutics?
Philip Kantoff is the current CEO of Convergent Therapeutics. They have also founded this company.
Is Convergent Therapeutics a funded company?
Convergent Therapeutics is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a Series A of $90M, raised on Apr 27, 2023.
How many employees does Convergent Therapeutics have?
As of Dec 31, 2022, the latest employee count at Convergent Therapeutics is 4.
What does Convergent Therapeutics do?
Convergent Therapeutics was founded in 2020 in the United States and operates within the biotechnology sector. Focus is placed on developing treatments for cancer through a proprietary approach involving dual-targeted radionuclide therapy. This method is applied to create CONV01-α, in which a monoclonal antibody is conjugated with actinium-225 to deliver radioisotopes specifically to prostate cancer cells.
Who are the top competitors of Convergent Therapeutics?
Convergent Therapeutics's top competitors include Radionetics, Nuage Therapeutics and Emtora Biosciences.
What products or services does Convergent Therapeutics offer?
Convergent Therapeutics offers CONV01-α and Radioantibodies.
Who are Convergent Therapeutics's investors?
Convergent Therapeutics has 3 investors. Key investors include Orbimed, RA Capital, and Novo Holdings.